User profiles for H Kerstjens

Huib Kerstjens

Dept of Pulmonolgy and Tuberculosis, University Medical Center Groningen, the …
Verified email at umcg.nl
Cited by 25685

Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel …

…, ST Holgate, P Ind, G Joos, H Kerstjens… - European …, 1999 - Eur Respiratory Soc
A Task Force supported by the European Respiratory Society was set up in 1997 in order to
address the major issues relevant to difficult/therapy-resistant asthma. Although the group of …

Decline of FEV1 by age and smoking status: facts, figures, and fallacies

HA Kerstjens, B Rijcken, JP Schouten, DS Postma - Thorax, 1997 - ncbi.nlm.nih.gov
… that the coefficient for age occurs between the ages of 18 to 25 and an HAM Kerstjens
Weill H. Blue-collar normative spirometric values for Caucasian and African-American men and …

Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated …

N Abello, HAM Kerstjens, DS Postma… - Journal of proteome …, 2009 - ACS Publications
Protein tyrosine nitration (PTN) is a post-translational modification occurring under the action
of a nitrating agent. Tyrosine is modified in the 3-position of the phenolic ring through the …

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials …

…, PG Gibson, JC De Jongste, HAM Kerstjens… - American journal of …, 2009 - atsjournals.org
Background: The assessment of asthma control is pivotal to the evaluation of treatment
response in individuals and in clinical trials. Previously, asthma control, severity, and …

A new perspective on concepts of asthma severity and control

…, JC De Jongste, HAM Kerstjens… - European …, 2008 - Eur Respiratory Soc
Concepts of asthma severity and control are important in the evaluation of patients and their
response to treatment but the terminology is not standardised and the terms are often used …

Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma

…, J Bousquet, HA Kerstjens, H Fox… - Clinical & …, 2004 - Wiley Online Library
Background Patients with severe asthma are often inadequately controlled on existing anti‐asthma
therapy, constituting an unmet clinical need. Objective This randomized, double‐blind…

[HTML][HTML] Tiotropium in asthma poorly controlled with standard combination therapy

HAM Kerstjens, M Engel, R Dahl… - … England Journal of …, 2012 - Mass Medical Soc
Background Some patients with asthma have frequent exacerbations and persistent airflow
obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists (…

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study

…, SJ Langley, A Woodcock, HAM Kerstjens… - American journal of …, 2003 - atsjournals.org
Antagonizing the effect of interleukin (IL)-5 is a potential new treatment strategy in allergic
disorders. We evaluated the safety, biological activity, and pharmacokinetics of SCH55700 , a …

[HTML][HTML] Endobronchial valves for emphysema without interlobar collateral ventilation

…, JE Hartman, HAM Kerstjens… - New England journal …, 2015 - Mass Medical Soc
Background Bronchoscopic lung-volume reduction with the use of one-way endobronchial
valves is a potential treatment for patients with severe emphysema. To date, the benefits have …

[HTML][HTML] Mepolizumab for eosinophilic chronic obstructive pulmonary disease

…, P Chanez, GJ Criner, HAM Kerstjens… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic
phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed …